A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

July 31, 2015
Updated Tenofovir Is Safer for Bones and Kidneys
An updated version of Viread (tenofovir) offers slightly better viral suppression and improves indicators of kidney and bone health, compared with the current version of the drug.
July 30, 2015
In Seattle, HIV Hits Younger Gays Less as Racial Disparities Emerge
Researchers have charted how HIV has affected older generations of gay men in the Seattle area worse than their younger counterparts and how, in more recent years, racial disparities have emerged.
San Francisco Effort to Treat HIV the Day of Diagnosis is a Success
A program in San Francisco has succeeded in getting people on antiretroviral treatment the day they are diagnosed with HIV and in shortening the time until they have an undetectable viral load.
July 29, 2015
Few U.S. Youths Have HIV Under Control After Diagnosis
Just 7 percent of American youths recently diagnosed with HIV achieved an undetectable viral load during a two-year study.
Gay Meth Use Accounts For 1 in 6 New HIV Cases in Seattle Area
Crystal meth use among gay men in King County, Washington, which includes Seattle, accounts for an estimated 16 percent of new HIV transmissions.
July 28, 2015
A New Way That HIV Exploits the Immune System
HIV uses a viral protein to manipulate the immune system into suppressing natural antiviral responses so it can more easily establish an infection.
Paying South African Girls to Stay in School Doesn’t Lower HIV Rate
A program that offered cash incentives for girls living in a poor section of South Africa failed to lower the HIV infection rate among them.
July 27, 2015
In Those With HIV, Best to Treat Hep B With Two Drugs
Among HIV-positive people, it is preferable to treat hepatitis B with a two-drug regimen rather than with monotherapy.
Some PrEP Success Among White and Latino Gay Youth
Young gay and bisexual men adhered moderately well to PrEP in a recent trial, but adherence dropped over time and was very poor among black and mixed-race participants.
New HIV Med Doravirine Has Half of Sustiva’s Side Effect Rate
Merck’s next-generation NNRTI doravirine (MK-1439) suppresses HIV as well as Sustiva (efavirenz) and leads to half the rate of side effects.
July 24, 2015
Some Western Gay Men Consider Viral Load in Safer-Sex Decisions
HIV-negative gay men in Seattle as well as Australia are taking their partners’ viral load, treatment or HIV testing history into account when making decisions about condom use.
Non-Daily PrEP Likely Works For Anal, Not Necessarily Vaginal, Sex
Research into the metabolization of Truvada suggests that non-daily-dosing protocols for PrEP offer high protection against HIV infection through anal sex, while vaginal sex protection is up for debate.
Individuals’ Genes Affected HIV Vaccine Efficacy
Specific variations in personal genes among study participants played a part in determining the efficacy of an HIV vaccine that was moderately successful among Thai volunteers.
Financial Incentives Encourage African Men to Be Circumcised
Food vouchers succeed in increasing the rate of voluntary male medical circumcision (VMMC) among Kenyan men.
FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3
The FDA has approved BMS's Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.
FDA Green Lights AbbVie’s Technivie for Genotype 4 of Hepatitis C
The FDA has approved AbbVie’s single-tablet combination regimen Technivie plus ribavirin to treat genotype 4 of hepatitis C virus among those without cirrhosis.
July 23, 2015
No Benefit to Treating Unconfirmed TB in Advanced HIV Cases
Providing tuberculosis treatment to people with very low CD4 counts who are just starting HIV therapy and do not have confirmed TB does not reduce the risk of death compared with giving ARVs and isoniazid preventive therapy for TB.
BMS’s Maturation Inhibitor Shows Promise
Bristol-Myers Squibb’s investigational next-generation maturation inhibitor BMS-955176 demonstrated good activity against HIV when paired with Reyataz (atazanavir) in a recent small study.
Intervention Ups Adherence to HIV Meds, Reduces Viral Load
An intervention has succeeded in motivating people with HIV to adhere to their antiretroviral regimens, ultimately reducing viral load.
July 22, 2015
HIV/Hep C Coinfection Increases Risk of Organ Rejection
People coinfected with HIV and hepatitis C are more likely to experience rejection of a transplanted liver than those who are monoinfected with either virus.
Many Cancers Are More Fatal If Someone Has HIV
People living with HIV have a greater likelihood of dying from numerous common cancers when compared with HIV-negative people.
Intercourse-Based PrEP Yields Lower Adherence Than Daily Dosing
People taking PrEP to prevent HIV tend to follow the standard daily-dosing regimen better than intermittent dosing schedules based on the timing of sexual acts.
BMS HIV Attachment Inhibitor Gets FDA Breakthrough Nod
The FDA has granted a breakthrough designation to Bristol-Myers Squibb’s investigational HIV attachment inhibitor BMS-663068.
July 21, 2015
Excellent Adherence, No New HIV Cases in Heterosexual PrEP Trial
Heterosexual participants in a study of Truvada as pre-exposure prophylaxis in Botswana apparently adhered to PrEP at very high rates, and there were no new HIV infections among them.
Cuba Is First Nation to Stop Mother-to-Child HIV Transmission
The World Health Organization has certified that Cuba has become the first country to eliminate mother-to-child transmission of HIV and syphilis.
Lack of Food Is Tied to Doing Poorly on HIV Treatment
People receiving treatment for HIV who lack sufficient food are more likely to have a detectable viral load than those who have enough to eat.
UNAIDS Goals of Testing and Treating HIV in Africa Look Achievable
International goals to test and treat high proportions of HIV-positive people by the decade’s end may be achievable in some sub-Saharan African nations.
Teen Has Viral Remission 12 Years After Stopping HIV Meds
An 18-year-old French teenager who contracted HIV from her mother has maintained control of the virus for 12 years after stopping antiretroviral treatment.
Gay and Bi Men Adhere Well to PrEP in U.S. Real-World Study
Transgender women and gay and bi men adhered at high rates to Truvada as PrEP in an American real-world study of the HIV prevention method, especially if they were at higher risk of contracting the virus.
Early HIV Treatment’s Benefits Examined More Closely
A new analysis of the major trial that provided gold-standard scientific proof supporting early treatment of HIV has illustrated in greater depth the many benefits of starting antiretrovirals soon after diagnosis and when CD4 counts are high.
July 20, 2015
New Proof That Passing On HIV While Undetectable Is Very Unlikely
A major study lends support to the belief that fully suppressing HIV through treatment makes transmitting the virus highly unlikely, at least among heterosexuals in this case.
HIV Treatment Takes Longer to Suppress Higher Viral Loads
Starting HIV treatment with a higher viral load tends to increase the time it takes to suppress the virus, extending the window of time when an individual may still be infectious. 
July 17, 2015
Non-Infectious Diseases Will Surge in Aging HIV Population
As the HIV population ages, non-communicable diseases will rise among them, in particular heart disease, as well as the use of medications for those diseases that may conflict with antiretrovirals.
July 16, 2015
Achieving Long-Term HIV Suppression Could Be Easier Than Expected
The reactivation rate of cells latently infected with HIV is much lower than previously thought, suggesting that the effort to incite long-term suppression of the virus without daily antiretroviral treatment may prove less daunting.
July 15, 2015
Prioritizing PrEP for High-Risk Kenyans Likely Spells Success
A pre-exposure prophylaxis rollout in Kenya would be the most effective if PrEP is prioritized for those at highest risk for infection.
July 14, 2015
Early HIV Treatment Especially Benefits Older People
Starting HIV treatment with a high viral load leads to a much greater reduction in death rates for people ages 45 to 65, compared with younger people with HIV
July 13, 2015
Keeping Latent HIV Dormant May Lead to Functional Cure
A natural compound has been found to significantly reduce the rate of reactivation of immune cells latently infected with HIV, suggesting a new potential route to a functional cure for the virus.
July 10, 2015
Treating HIV Low Appetite With Medical Pot Backed by Weak Science
Research supporting various uses of cannabis or cannabis-based medications provides low-quality evidence and is often beset with significant potential for bias.
July 09, 2015
Community-Based HIV Prevention Spending Reaps Huge Savings
Investing in community-based HIV prevention programs translates to a five-fold savings in avoided costs associated with treating the virus, according to a study of such programs in Ontario, Canada.
July 08, 2015
HIV Meds Should Work for Most Drug-Resistant Strains in the UK
Drug-resistant strains of HIV continue to be transmitted in the UK, but this doesn't appear likely to have a major effect on the treatment response.
Hepatitis C Has Large Impact in Sub-Saharan Africa
Sub-Saharan Africa has a high prevalence of hepatitis C, especially among HIV-positive individuals.
July 07, 2015
UNAIDS Calls for Scale-Up in Global HIV Fight
UNAIDS and the Lancet Commission have called for greater access to HIV treatment and greater prevention efforts worldwide, lest infection rates rebound.
AHF Refuses to Correct Misleading Anti-PrEP Ad
A major HIV physicians group has requested that AIDS Healthcare Foundation correct or retract a key point in the stringently anti-PrEP ad AHF placed in gay publications nationwide.
July 06, 2015
Hep C Coinfection Increases Death Risk in Drug Users With HIV
The raised risk of death resulting from injection drug use among people with HIV is substantially explained by hep C coinfection among that population.
July 03, 2015
Fact-Checking AIDS Healthcare Foundation's Latest Anti-PrEP Screed
AIDS Healthcare Foundation published an ad criticizing pre-exposure prophylaxis (PrEP) in various gay publications around the country.
July 02, 2015
Gilead Seeks FDA OK for 3rd Combo Pill With New Tenofovir
Gilead Sciences has applied to the FDA for approval of yet another combination HIV tablet including an updated version of tenofovir.
July 01, 2015
Success for Anti-HIV Gene Therapy in Mice
Researchers significantly reduced HIV levels in mice with a genetic therapy that induces immune cells to better fight the virus.
CDC Awards $216M to 90 Community Groups to Prevent HIV
Funding also creates 'Prevention Partnerships' that pair up community-based organizations to share expertise and resources.
Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?

July 2015
June 2015
May 2015
April 2015
March 2015
February 2015
January 2015
December 2014
November 2014
October 2014
September 2014
August 2014
July 2014
June 2014
May 2014
April 2014
March 2014
February 2014
January 2014
December 2013
November 2013
October 2013
September 2013
August 2013
July 2013
June 2013
May 2013
April 2013
March 2013
February 2013
January 2013
December 2012
November 2012
October 2012
September 2012
August 2012
July 2012
June 2012
May 2012
April 2012
March 2012
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007
January 2007
December 2006
November 2006
October 2006
September 2006
August 2006
July 2006
June 2006
May 2006
April 2006
February 2006
October 2005

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2015 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.